VisioCyt® Bladder obtains temporary coverage under the RIHN 2.0 program: a major breakthrough for the non-invasive diagnosis of bladder cancer

VisioCyt® Bladder, an innovative non-invasive solution for diagnosing bladder cancer, is now covered under the national RIHN 2.0 program following a favorable joint evaluation by the French National Authority for Health (HAS) and the Directorate General for Health (DGS)

The French National Authority for Health (HAS) issues a favorable opinion on the exceptional reimbursement coverage of VisioCyt® Bladder.

VitaDX welcomes the favorable opinion issued by the French National Authority for Health (HAS) on June 5, 2025, regarding the exceptional reimbursement coverage of digitized and artificial intelligence–assisted urinary cytology using the medical device VisioCyt® Bladder for the surveillance of recurrences of non–muscle-invasive bladder tumors (NMIBC).